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Nearly half of the world’s population is at risk for dengue, yet no licensed vaccine or anti-
viral drug is currently available. Dengue is caused by any of four dengue virus serotypes
(DENV-1 through DENV-4), and infection by a DENV serotype is assumed to provide life-
long protection against re-infection by that serotype. We investigated the validity of this fun-
damental assumption during a large dengue epidemic caused by DENV-2 in Iquitos, Peru,
in 2010–2011, 15 years after the first outbreak of DENV-2 in the region.
Methodology/Principal Findings
We estimated the age-dependent prevalence of serotype-specific DENV antibodies from
longitudinal cohort studies conducted between 1993 and 2010. During the 2010–2011 epi-
demic, active dengue cases were identified through active community- and clinic-based
febrile surveillance studies, and acute inapparent DENV infections were identified through
contact tracing studies. Based on the age-specific prevalence of DENV-2 neutralizing anti-
bodies, the age distribution of DENV-2 cases was markedly older than expected. Homolo-
gous protection was estimated at 35.1% (95% confidence interval: 0%–65.2%). At the
individual level, pre-existing DENV-2 antibodies were associated with an incomplete reduc-
tion in the frequency of symptoms. Among dengue cases, 43% (26/66) exhibited elevated
DENV-2 neutralizing antibody titers for years prior to infection, compared with 76% (13/17)
of inapparent infections (age-adjusted odds ratio: 4.2; 95% confidence interval: 1.1–17.7).
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Conclusions/Significance
Our data indicate that protection from homologous DENV re-infection may be incomplete in
some circumstances, which provides context for the limited vaccine efficacy against DENV-
2 in recent trials. Further studies are warranted to confirm this phenomenon and to evaluate
the potential role of incomplete homologous protection in DENV transmission dynamics.
Author Summary
Dengue is a mosquito-borne viral illness that imposes a tremendous public health burden
on tropical and sub-tropical regions. An estimated 390 million infections occur globally
each year, and up to 4 billion people are at risk. Dengue is caused by four dengue virus
(DENV) serotypes (DENV-1 to DENV-4). Infection with any DENV can lead to a range
of disease outcomes, from mild febrile illness to severe, hemorrhagic manifestations and
death. Infection by one serotype has been assume to provide complete and lifelong protec-
tion against re-infection by the same serotype, and to our knowledge, instances of re-infec-
tion by the same serotype have not been rigorously documented. However, few long-term
studies have been conducted in such a way that re-infection by the same serotype could be
observed, if it did in fact occur. Our study provides evidence that re-infection may occur
in certain circumstances. We draw from data collected during a 2010–2011 DENV-2 epi-
demic in northeastern Peru, 15 years after the initial DENV-2 outbreak in the region. This
finding has significant implications for our understanding of dengue epidemiology and for
dengue vaccine formulation, which may need to consider multiple genotypes of each sero-
type. Data from other long-term dengue epidemiology studies should be analyzed to deter-
mine if homologous re-infection is a more widespread phenomenon.
Introduction
Dengue is a mosquito-borne viral illness that imposes a tremendous public health burden on
tropical and sub-tropical regions. An estimated 390 million infections occur globally each year,
and up to 4 billion people are at risk [1]. Dengue is caused by four dengue virus (DENV) sero-
types (DENV-1 to DENV-4). Infection with any DENV can lead to a range of disease out-
comes, from mild febrile illness to severe, hemorrhagic manifestations and death. Although
DENV infections are often inapparent, many dengue cases require hospitalization, which can
overwhelm medical infrastructure during epidemics. There are no specific antiviral therapeu-
tics and currently no licensed vaccine.
DENVs display substantial inter-serotypic genetic heterogeneity. Serotypes share less than
70% identity at the nucleotide level and less than 80% identity at the amino acid level [2], simi-
lar to the genetic distance between Japanese encephalitis virus and West Nile virus. Infection
by one DENV serotype appears to induce relatively short term protection against infection by a
heterologous serotype [3,4]. Thereafter, an individual returns to being susceptible to heterolo-
gous infection [5,6]. Importantly, an individual’s specific DENV infection history can either
enhance or attenuate the severity of disease they experience during subsequent, sequential
exposures [7–9].
Although DENVs are genetically and phenotypically diverse within serotypes, infection
with one strain of a serotype is thought to induce lifelong protection against infection by all
other strains of the homologous serotype [10]. This assumption, however, lacks direct support,
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in part because of difficulty in obtaining the appropriate epidemiological data and the absence
of an adequate animal model for studying DENV pathogenesis. In neutralization assays, serum
and monoclonal antibody titers can vary markedly depending on the viral strain used [11],
which suggests that intra-serotype variability could be epidemiologically important. If re-infec-
tion with a new strain of a homologous DENV serotype can produce symptomatic disease,
even if tempered by imperfect neutralization, this would have significant ramifications for the
ongoing development of DENV vaccines [12] and our understanding of DENV transmission
dynamics.
Between late 2010 and early 2011, Iquitos, Peru, experienced an unprecedented outbreak of
severe dengue caused predominantly by an American/Asian genotype of DENV-2
(AA-DENV-2) [13,14]. The number of cases (~25,000) reported by the local health authorities
[15] far exceeded any previous epidemic in Iquitos, with greater than 2,500 cases per week
reported on several occasions. Many cases required hospitalization, which overwhelmed the
local health care system [16]. This epidemic occurred 15 years after DENV-2 (American geno-
type; Am-DENV-2) was first detected in Iquitos, which caused a large outbreak of febrile illness
starting in 1995. In the intervening years between the two outbreaks, few isolates of DENV-2
were detected in Iquitos [17]. The 1995 introduction of Am-DENV-2 caused a large outbreak
of febrile illness and led to a high prevalence of DENV-2 antibodies among Iquitos residents
[18,19]. Given the high DENV-2 antibody prevalence and the sheer magnitude of the dengue
outbreak, we postulated that the pre-existing antibodies failed to protect against reinfection
and disease. We tested this hypothesis by analyzing population- and individual-level infection
patterns, utilizing data from ongoing clinic-and community-based febrile surveillance and a
long-term series of longitudinal studies on the seroprevalence of DENV in Iquitos.
Methods
Ethical considerations
All human subjects protocols (see [20] for protocol numbers and details) were in compliance
with all applicable US Federal regulations governing the protections of human subjects. All
protocols received approval from the institutional review boards of all relevant participating
institutions (US Naval Medical Research Center, US Naval Medical Research Unit No. 6 [previ-
ously US Naval Medical Research Center Detachment], University of California—Davis, the
Peruvian Instituto Nacional de Salud, and Universidad Peruana Cayetano Heredia). In addi-
tion, protocols were reviewed and approved by the Loreto Regional Health Department, which
oversees health-related research in Iquitos. Written informed consent was provided by adult
study participants or by parents or guardians of participating minors.
Prospective longitudinal cohorts
Samples used for estimating serotype-specific antibody prevalence between 1993 and 2010
were collected from five different longitudinal cohort studies [20]. Cohort participation was
restricted to participants above the age of 5; four of the cohorts included adult participants
above the age of 17. Serum samples were collected at 6 to 12 month intervals and were tested
for DENV neutralizing antibodies by the plaque reduction neutralization test (PRNT). In the
first study (the source data for years 1993 (n = 284), 1994 (n = 196), 1995 (n = 162), and 1996
(n = 368)), yearly serum samples were collected from school-aged children (5–22 years) who
attended six schools in Iquitos [18]. The second cohort (under the study name “Entomological
Correlates of Dengue Control”; the source data for years 1999 (n = 1,444) and 2002
(n = 2,055), and part of the source data for 2004 (combined n = 3,068)) was initiated in 1999,
continued through 2005 [19], and included a geographically stratified sample of approximately
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2,400 participants (school age children and their family members). After the base cohort was
established, follow-up samples were collected at approximately 6-month intervals. The third
cohort (study name “Dengue Vector Control System”; part of the source data for 2004 (com-
bined n = 3,068)) was initiated in 2004, with 2,415 participants providing a baseline serum
sample [19]. Follow-up serum samples were collected in January—February 2005 and October
2005. The fourth cohort (study name “Active Dengue Surveillance and Predictors of Disease
Severity in Iquitos, Peru”; the source data for 2006 (n = 2,356), and part of the source data for
years 2008 (combined n = 2,137) and 2010 (combined n = 3,131)) was initiated in 2006, and
included approximately 2,400 participants at baseline. Samples were collected approximately
every six months until mid-2010. The final cohort (“Measuring Entomological Risk for Den-
gue”; part of the source data for years 2008 (combined n = 2,137) and 2010 (combined
n = 3,131)) was initiated in late 2007 among approximately 2,400 participants [21] and is ongo-
ing. Individuals above the age of five years residing in study neighborhoods were invited to par-
ticipate. Longitudinal serum samples were provided between 6 and 12 month intervals [20].
Seroprevalence estimates presented in this manuscript are based on laboratory analysis and
data generated at the time of each study.
Virus neutralization assays
PRNTs with a semi-solid overlay were used to quantify serotype-specific neutralizing antibod-
ies, as previously described [8]. Samples that reduced the number of plaques by 70% (i.e.
PRNT70) relative to normal human serum at a serotype-specific cutoff dilution were consid-
ered positive. Cut-off dilutions were set at 1:60 for DENV-1, DENV-2, and DENV-3, and 1:40
for DENV-4 (all after the addition of virus). Positive and negative control human sera were
included with each set of samples analyzed. For routine seroprevalence studies conducted in
prior to 2005, positivity (e.g., 70% reduction at 1:60 dilution) was based on samples tested at
1:60 dilution (after the addition of virus). For routine seroprevalence studies conducted after
2005, positivity (e.g., 70% reduction at 1:60 dilution) was based on titers were estimated by
probit regression, using a dilution series of 1:40, 1:80, 1:160, and 1:640, after the addition of
virus. For quantifying end point titers, samples were diluted four-fold from 1:40 to 1:10240 and
tested in duplicate; final titers were estimated by probit regression.
For seroprevalence studies, test viruses were DENV-1 16007 (DHF case from Thailand,
1964), DENV-2 16681 (Asian I genotype; DHF case from Thailand, 1964), DENV-3 IQD1728
(DF case from Peru, 2002), and DENV-4 1036 (DF case from Indonesia, 1976). DENV-2
16681 (Asian genotype) was selected for the seroprevalence assays because previous experi-
ments in our laboratory showed that this strain minimized a cross-reactive response from
DENV-1 infection [9]. For comparing antibody titers against Am-DENV-2 and AA-DENV-2
genotypes, viral strains were IQT2124 (American genotype, Iquitos, 1995), IQT2913 (Ameri-
can genotype, Iquitos, 1996), NFI1159 (American/Asian genotype, Iquitos 2010), and NFI1166
(American/Asian genotype, Iquitos, 2010).
Febrile surveillance
Clinic-based surveillance was conducted as described previously [17]. Briefly, participants 5
years of age or older were enrolled when reporting to outpatient clinics or hospitals in Iquitos
within 7 days of onset of symptoms (fever, plus one or more other symptoms, such as head-
ache, muscle pain, or retro-orbital pain). Participants younger than 5 years of age were enrolled
only when presenting with severe disease, such as hemorrhagic manifestations. As a result,
very few participants of the surveillance study were younger than 5 (<1% of febrile cases
enrolled overall and<1% of DENV-2 cases enrolled during the 2010–2011 epidemic). Within
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longitudinal cohorts underway during the 2010–2011 epidemic, dengue cases were identified
through a community-based door-to-door active surveillance [8]. Participants’ homes were vis-
ited three times per week by technicians to inquire about residents with acute febrile illness.
For both clinic-based and community-based surveillance, acute-phase serum samples were col-
lected at time of presentation and convalescent-phase serum samples were collected two weeks
to a month later. Confirmed dengue cases were defined as positive by immunofluorescence
assay (IFA) in tissue culture, by reverse transcriptase polymerase chain reaction (RT-PCR), or
IgM ELISA, as previously described [17]. Based on clinic-based febrile surveillance, 84%
(n = 433) of all DENV isolates during the 2010–2011 epidemic were DENV-2, 13% (n = 69)
were DENV-4 and 3% (n = 13) were DENV-1.
Contact tracing studies
Contact tracing studies were ongoing during the 2010–2011 epidemic as part of a project aim-
ing to capture inapparent infections and to measure the importance of human movement pat-
terns in dengue virus transmission [21]. Upon identification of a DENV-positive febrile case
through active, community-based surveillance, a cluster investigation was initiated. Participa-
tion was then solicited from all individuals living in houses recently visited by the DENV case
and in neighboring households. All participants provided blood samples at days 0 and 15 to
test for DENV infection by RT-PCR. Individuals participating in the cluster investigations
were monitored for manifestations of febrile illness.
Expected and observed age distributions of DENV-2 cases
The age distribution of clinical cases is determined by the age structure of the population and
at least three key epidemiological processes: immunity, the force of infection (risk of exposure)
and the development of clinical symptoms. Given age-specific profiles for each of these and the
age structure of the population, the expected age distribution of cases can be inferred. If we
consider the scenario of a novel pathogen invading a completely susceptible population with
no age dependence in risk of exposure or manifestation of disease, then the age distribution of
cases would mirror the age distribution of the population. By contrast, the re-introduction of
an immunizing pathogen should result in a shift of cases to lower age groups who have no
prior exposure and, therefore, no protection. We would expect this shift would be less marked,
however, if immunity were imperfect.
To compare the observed age distribution of DENV-2 cases in clinics and hospitals to the
age distribution we computed an expected age distribution of cases based on: (1) the total num-
ber of observed cases (say N), (2) the age distribution of individuals who appeared at the clinics
and hospitals with a febrile illness[17] and participated in the febrile surveillance studies in
past years, and (3) age-based distribution of DENV-2 neutralizing antibodies in the months
preceding the epidemic. From (2) and (3) we computed the expected probability that the next
case that appears in the clinics with DENV-2 will be of a particular age (for each age group).
Specifically, for each age group, we found from (2) what percent of that age group is still sus-
ceptible to DENV-2 (say, for age group i, pi) and from (3) we found what percent of those who
appeared at a clinic or hospital were from that age group (say, for age group i, ai). Letting qi be
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This equation is based on the assumption that an individual of any age is equally likely to
become infected. By multiplying these probabilities by the total number of DENV-2 cases iden-
tified at the clinics and hospitals, we arrive at the expected number of cases by age that would
have been expected if the patterns of age at time of infection were identical during the epidemic
as compared with before the epidemic (specifically, for age group i, qi x N). While we included
individuals in the 0–5 age range in the calculations, cases in this age range have limited impact
on the model overall since few were enrolled in the febrile surveillance study prior to or during
the DENV-2 epidemic.
We further investigated the possibility of incomplete homologous protection against symp-
tomatic infection by adjusting the age-based distribution of DENV-2 neutralizing antibodies
(3). Above we assumed that the presence of neutralizing antibodies conferred immunity, and
that only those without these antibodies could become symptomatically infected in the future.
To investigate imperfect immunity, we assumed that the percentage of the individuals with neu-
tralizing antibodies did not directly translate into the percentage of individuals who were
immune. Letting γ be the percent of those who have protective antibodies, we recomputed qi as:
qi ¼
ðg  pi þ 1 gÞai
Sjðg  pj þ 1 gÞaj
We then vary γ from 0 (corresponding to zero protection) to 1 (corresponding to complete pro-
tection from disease resulting from infection).
For each value of γ, we calculate a distribution of cases by age. We can then compare this
“expected” distribution with the “observed” distribution of cases at the clinics. By calculating
the probability of observing a deviation from the expected distribution as large as or larger
than the one observed, we can identify which values of γ would not result us in concluding that
there is a statistically significant difference between the expected and observed distributions.
Exploiting the duality between hypothesis tests and confidence intervals, and using a cutoff of
5% for the above probability for each value of γ, we create a 95% confidence interval. The value
of γ that maximizes this probability we use as our point estimate of the value of γ that is most
supported by the data and the model.
Results
The 2010–2011 DENV-2 outbreak
Based on two cohort studies that together sampled people (n = 3127) in neighborhoods located
throughout the city [8,20,21], in early 2010 the prevalence of neutralizing antibodies among
Iquitos residents was approximately 82.1% (95% CI 80.7%–83.4%) for DENV-1, 74.5% (95% CI
73.0%–76.1%) for DENV-2, 67.1% (65.4%–68.7%) for DENV-3, and 40.7% (95% CI 38.9%—
42.4%) for DENV-4 (Fig 1), reflecting the order of DENV invasions since 1990 [17,20]. The
seroprevalence of DENV-1 and DENV-2 neutralizing antibodies was strongly age-dependent
(Fig 1, panel A), as was the prevalence of multitypic neutralization profiles (neutralizing anti-
bodies against two or more serotypes; Fig 1, panel B). In contrast, the prevalence of DENV-3
and DENV-4 neutralizing antibodies was less age-dependent, consistent with the history of den-
gue outbreaks in Iquitos. The age-specific DENV-2 seroprevalence, spiking between the 10–14
and 15–19 year old age groups (Fig 1, panel A), and analysis of cohort studies dating back to
1993 [18] strongly suggest that these titers were due to prior exposure during an Am-DENV-2
outbreak starting in 1995 rather than cross-reactive antibody for heterologous DENV serotypes.
Given that the observed DENV-2 antibody prevalence in the Iquitos population was pri-
marily the result of prior exposure to Am-DENV-2 ten years earlier and the sheer magnitude
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of the 2010–2011 dengue outbreak, we postulated that the pre-existing antibodies failed to pro-
tect against reinfection and disease. Although we did not detect any individuals with virologi-
cally-confirmed acute DENV-2 infections in both 1995 and 2010–2011, likely because of
limitations of febrile surveillance activities in the mid-1990s and challenges in linking
Fig 1. Age distribution of DENV neutralizing antibodies in 2010. Samples were collected between March
and June 2010, approximately 6 months prior to a large dengue epidemic largely caused by American/Asian
genotype DENV-2. Panel A: Age distribution of serotype-specific DENV neutralizing antibodies. Panel B: Age
distribution of number of prior DENV infections. Naïve indicates absence of detectable DENV neutralizing
antibodies against any serotype, monotypic indicates DENV neutralizing antibodies against one serotype,
and multitypic indicates DENV neutralizing antibodies against two or more serotypes.
doi:10.1371/journal.pntd.0004398.g001
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participant results across studies, we were able to test this hypothesis by analyzing population
and individual level infection patterns.
Population-level infection patterns
Age-dependent patterns of infection and disease in a population are in part a reflection of the
extent of pre-existing immunity [22]. Given the high prevalence of DENV-2-neutralizing anti-
bodies in 2010 among individuals older than 15 years (86.9%; 95% CI: 85.5%—88.2%; Fig 1,
panel A), we expected most new cases to occur in children. We therefore compared the
observed age distribution of new AA-DENV-2 cases identified through clinic-based surveil-
lance systems [17] with an expected distribution, based on the age-specific prevalence of
DENV-2 neutralizing antibodies prior to the epidemic and the age distribution of febrile cases
that participated in previous years of the studies. The observed distribution included many
more cases in older age groups, especially 20–40 year-olds, than was expected given the age dis-
tribution of DENV-2 neutralizing antibodies prior to the introduction of AA-DENV-2 (Fig 2,
panel A). In comparison, for DENV-4, first introduced in 2008 and, therefore, with a much
more recent history in Iquitos, the age distribution of dengue cases was consistent with what
would be predicted based on age structure and detected immunity levels in the population (Fig
2, panel B). We subsequently generated expected distributions of AA-DENV-2 infections
assuming several levels of partial immunity conveyed by the pre-existing DENV-2 antibodies.
We found that we could reproduce the observed distribution of DENV-2 cases when protection
was incomplete (Fig 2, panels C and D), with an estimated homologous protection of 35.1%
(95% CI: 0%–65.2%) providing a best fit with the observed data.
The observed distribution of AA-DENV-2 cases could have been influenced by age-specific
differences in infection rates. We addressed this concern using data from a case-control contact-
tracing study [21] that captured inapparent DENV-2 infections and DENV-negative individuals
concurrently. We compared the age-distribution of infected and uninfected individuals (Fig 3)
and found them to be very similar (DENV-2 infections: mean age 31.4 years, standard deviation
19.3 years, n = 75; DENV-negative: mean age 28.5 years, standard deviation 18.0 years, n = 2333).
To address the possibility that the observed DENV-2 neutralizing antibodies were the result
of cross-reaction from heterologous DENV infection, we utilized multiple cross-sectional sam-
ples from cohort studies conducted in Iquitos since the early 1990s [8,18,19,23]. If cross-reac-
tion was driving the observed age dependence of DENV-2 neutralizing antibodies, we would
expect that the DENV-2 antibody prevalence in adults to have increased incrementally over
the years, including during periods such as 2001–2010 that were dominated by transmission of
heterologous serotypes and near absence of confirmed clinical DENV-2 infections. Yet, among
individuals born prior to 1995, the observed pattern was consistent with DENV-2 neutralizing
antibodies generated largely during the 1995 outbreak (Fig 4).
In 1993, following the DENV-1 epidemic and prior to the known emergence of DENV-2,
most of the population had DENV-1 antibodies (Fig 4, panel A), yet fewer than 10% had
DENV-2 antibodies (Fig 4, panel B; see also [18]). Even the few DENV-2 antibodies observed
prior to 1995 were likely short-term cross-reactive (heterotypic) antibodies from recent
DENV-1 infection, because the majority were in DENV-1 positive individuals, and only 32%
of DENV-2 antibody positive individuals maintained neutralizing antibodies during the next
sampling season (i.e., from 1993 to 1994). DENV-2 antibody prevalence spiked following the
1995 DENV-2 epidemic and was largely stable among individuals born prior to 1990 (i.e.,
those alive during the entirety of contemporary DENV transmission in Iquitos) from 1995 to
2010 (i.e., immediately preceding the second DENV-2 epidemic; Fig 4, panel B). For partici-
pants born after 1999 (i.e., following the first period of DENV-2 circulation), DENV-2
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antibody prevalence remained low until 2010, despite experiencing more than a decade of
DENV transmission (predominantly DENV-3 and DENV-4). These data indicate that DENV-
2 antibodies observed in adults prior to the 2010–2011 epidemic were predominantly due to
true DENV-2 infection (specifically, Am-DENV-2).
Fig 2. Expected versus observed DENV-2 and DENV-4 cases. The observed age distribution of cases of DENV-2 (dark green in panels A, C, and D) and
DENV-4 (dark purple in panel B). Using the ages of all febrile individuals that participated in a clinic-based febrile surveillance study[17], we built an empirical
estimate of the age distribution of individuals who sought treatment in Iquitos. By multiplying this distribution by the age-specific percent of the population with
serotype-specific dengue antibodies, we created serotype-specific expected age distributions of cases for DENV-2 and DENV-4 (light green in panel A and
light purple in panel B). We then adjusted the age- and serotype-specific immune levels and recalculated expected age distributions of cases for DENV-2 by
assuming, across all ages, either 25% or 50% of those who should have been immune were still susceptible to DENV-2 (light green in panel C and light green
in panel D, respectively).
doi:10.1371/journal.pntd.0004398.g002
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Individual-level infection patterns
The results from the population-level analysis indicate that some individuals with pre-existing
DENV-2 neutralizing antibodies prior to the 2010 epidemic were infected by AA-DENV-2 and
presented with clinically apparent disease. To address this possibility, we examined the serolog-
ical histories (see Methods) of individuals who had symptomatic or clinically inapparent
AA-DENV-2 infections (Table 1) and who had provided two or more samples (median 4 sam-
ples; range, 2–7 samples) in a longitudinal cohort study. Among AA-DENV-2 cases, 43% (26/
66) had consistently robust DENV-2 neutralizing titers (i.e., titers>60 for all pre-infection
samples; geometric mean titer, 267) prior to the symptomatic AA-DENV-2 infection. There
was a strong age dependence, consistent with the history of DENV circulation in Iquitos.
Among cases born prior to 1995, 61% had DENV-2 neutralizing antibodies prior to infection,
compared with 17% among those born during 1995 or later (Table 1). Among the clinically
inapparent AA-DENV-2 infections, 76% (13/17) had DENV-2 neutralizing antibodies prior to
infection, a prevalence similar to the study population at-large (73%) but higher than the symp-
tomatic infections (i.e., 43%; age-adjusted odds ratio 4.2, 95% confidence interval 1.1–17.7).
Among these AA-DENV-2-infected individuals (symptomatic and inapparent), the proportion
with pre-existing DENV-2 neutralizing antibodies was consistent for years leading up to the
2010–2011 epidemic, as was the magnitude of antibody titers (Table 2). Three individuals that
were monotypic for DENV-2 at the start of the study experienced virologically-confirmed
acute DENV-2 infections during the 2010–2011 epidemic; two were inapparent and one was
clinically apparent. These data suggest that AA-DENV-2 did infect individuals with pre-exist-
ing high titer DENV-2-neutralizing antibodies and are consistent with the notion that DENV-
2 antibodies provided partial protection against disease.
Fig 3. Proportion of DENV-2-infected and DENV-negative individuals by age group (in 5 year intervals). Individuals identified through a contract-
tracing study provided serum samples at day 0 and day 15 and were tested for active DENV infection by RT-PCR. Overlapping age distributions suggest that
there were no gross age-dependent differences in risk for infection within the study population.
doi:10.1371/journal.pntd.0004398.g003
Potential DENV-2 Re-infection in Peru
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004398 February 5, 2016 10 / 17
Our results suggest the possibility that Am-DENV-2 infection failed to generate antibodies
that robustly neutralize AA-DENV-2. To address this, we utilized pre-epidemic serum col-
lected between 2006 and 2010 from individuals who were later detected with AA-DENV-2
infections (n = 21) and compared end point titers against two strains of Am-DENV-2 and two
strains of AA-DENV-2 (Table 3). Robust neutralizing titers were observed against both geno-
types, although pre-epidemic titers were two-fold higher against Am-DENV-2 strains (mean,
363) compared with AA-DENV-2 strains (mean, 171). In contrast, post-epidemic serum
Fig 4. DENV-1 and DENV-2 neutralizing antibody prevalence by year and birth cohort. Samples were
collected from longitudinal cohort studies conducted in Iquitos between 1993 and 2010. Panel A: DENV-1
neutralizing antibody prevalence by year, based on birth cohorts. Panel B: DENV-2 neutralizing antibody
prevalence by year, based on birth cohorts.
doi:10.1371/journal.pntd.0004398.g004
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(2011–2012) collected from previously DENV-2-naïve individuals who were infected during
the 2010–2011 epidemic (n = 14) did not have higher titers using Am-DENV-2 test viruses
(mean, 739) compared with AA-DENV-2 (mean, 899; Table 3).
Discussion
We provide indirect evidence that challenges a fundamental assumption of dengue immunol-
ogy: that infection with one serotype conveys lifelong protection to reinfection by all strains
belonging to the same serotype. A newly introduced genotype of DENV-2 exhibited character-
istics similar to a novel serotype in a population with a high prevalence of DENV-2 neutralizing
antibodies. Moreover, we isolated DENV-2 virus from numerous individuals with pre-existing,
robust DENV-2 antibody titers. Epidemiological data from long-term longitudinal cohort
studies[20] show that pre-existing DENV-2 antibodies present in the adult population were
mostly a product of the invasion of an American strain of DENV-2 in 1995. Although these
antibodies did not appear to completely protect against infection with the new strain, they did
Table 1. Pre-epidemic DENV-2 neutralizing antibody prevalence among symptomatic and inapparent DENV-2 infections.
Symptomatic Inapparent All
Median age in 2010 (IQR1) 17 (13–42) 27 (16–45) 19 (14–43)
DENV-2 antibody prevalence2 43% (26/60) 76% (13/17) 51% (39/77)
< = 15yrs (born 1995 or later) 17% (4/24) 25% (1/4) 18% (5/28)
> 15yrs (born prior to 1995) 61% (22/36) 92% (12/13) 69% (34/49)
Geometric mean titer3 267 418 310
1 IQR indicates interquartile range (i.e., 25th and 75th percentiles).
2 Numbers in parentheses indicate antibody positive samples and the total number analyzed in each category.
3 Geometric mean titers are based on samples with detectable titers, and are aggregated across all pre-infection samples available for individuals.
doi:10.1371/journal.pntd.0004398.t001
Table 2. Pre-epidemic DENV-2 neutralizing antibody profiles of participants with subsequent confirmed DENV-2 infection in 2010–2011. Seroprev-
alence is based on a cutoff titer of 60. Geometric mean titers (GMT) are based on samples with detectable titers.
Years prior to infection
3 to 2 yrs 2 to 1 yrs 1 to 0.5 yrs  0.5 yrs
N1 54 64 60 34
Seroprevalence (95% CI) 59% (45%-72%) 59% (46%-72%) 58% (45%-71%) 59% (41%-75%)
Geometric mean titer2 320 337 263 370
1 If more than one sample was available for a participant within a particular time interval, only one sample was used in the calculations.
2 Geometric mean titers are based on samples with detectable titers.
doi:10.1371/journal.pntd.0004398.t002
Table 3. Neutralization of Am-DENV-2 and AA-DENV-2 test viruses using human serum from longitudinal cohort studies. Geometric mean titers
(GMTs) for the individual test viruses and the average of the two GMTs are shown.
American genotype DENV-2 test viruses American/Asian genotype DENV-2 test
viruses
Sera, collection years IQT2124 IQT2913 Average NFI1159 NFI1166 Average
Pre-epidemic, 2006–2010 (n = 24) 200 526 363 139 203 171
Post-epidemic, 2011–2012 (n = 14) 327 1150 739 871 927 899
doi:10.1371/journal.pntd.0004398.t003
Potential DENV-2 Re-infection in Peru
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004398 February 5, 2016 12 / 17
appear to provide partial protection against febrile illness, reducing the probability of disease.
Dengue epidemiology and vaccine development have long been complicated by the immuno-
logical interplay among serotypes at the level of the human host. Genetic and phenotypic het-
erogeneity may be sufficient to extend this interplay to the level of individual genotypes, which
markedly increases the complexity of the system[7] and could present further challenges for
the development of a suitable dengue vaccine[12,24].
One key piece of evidence in our study arises from the observation of more infections than
expected in older age groups. Our calculations for the expected age distribution of DENV-2
cases take into account the age-dependent participation in our febrile illness studies. Our previ-
ous analysis of DENV-3 and DENV-4 seroconversions did not indicate a substantial age-
dependent risk for infection [8]. Further, among confirmed infections, we did not observe a
marked age-dependent difference in risk for disease for DENV-3, and we observed only a mod-
est increase in disease risk among younger adults for DENV-4 [8]. Although others have
reported that disease risk may increase with age [25], this conclusion is based on indirectly
measured exposures and could be skewed by reporting biases. Additionally, in Iquitos, the
large majority of individuals older than 20 years (~90%; Fig 1, panel B) have been exposed to at
least two serotypes, which would be expected to dramatically reduce the risk of disease upon
infection relative to younger participants [8]. Therefore, we feel that our assumptions are con-
servative and likely underestimate the relative number of cases among older participants.
Our results depend in part on PRNTs, which are widely considered the most specific sero-
logical tests available for DENV. Yet even PRNTs can be prone to cross-reaction in some cir-
cumstances [26]. To reduce potential for cross-reaction, we used more stringent conditions
(PRNT70 at 1:60 dilution cutoff) than used in most dengue vaccine [12] or dengue epidemio-
logical studies [27], which often use a 50% reduction (PRNT50) threshold. We conducted an
additional evaluation of even more stringent conditions (90% reduction threshold, or
PRNT90) had only modest reductions in seroprevalence (67% for PRNT90 at a 1:60 dilution
cutoff versus 73% for PRNT70 as reported above). Furthermore, among individuals who had
pre-existing DENV-2 neutralizing antibodies and were infected during the 2010–2011 epi-
demic, more than half had titers greater than 300 (using 70% reduction threshold). This titer
(323, using the lower 50% reduction threshold) was proposed as a cutoff for differentiating
“susceptible” from “non-susceptible” subjects based on limited data from a Thai cohort [28].
More importantly, we directly address the issue of cross-reaction by utilizing samples col-
lected prior to the first documented DENV-2 outbreak in 1995. Detectable DENV-2 antibody
prevalence was low prior to DENV-2 emergence in Iquitos, spiked immediately following
DENV-2 emergence in 1995, and remained stable among adults up to the 2010–2011 epidemic
(Fig 4). Further, the prevalence of antibodies in individuals born after the major DENV-2
transmission period (1995–1999) was low, despite potential for cross-reaction following epi-
demics of DENV-3 and DENV-4 between 2001 and 2009. The absence of a large age shift in
overt disease during the AA-DENV-2 epidemic also supports our conclusion. In contrast, the
2007–2008 re-emergence of DENV-2 in Brazil was accompanied by an age shift in dengue
cases, with a sharp increase in disease incidence in younger age groups relative to older individ-
uals [29]. Notably in the case of Brazil, AA-DENV-2 had circulated during earlier outbreaks
(before 2002) prior to re-emerging in 2007.
It is not clear if the homologous serotype re-infection we identified is unique to the DENV-
2 genotypes we studied (i.e., American genotype followed by American/Asian genotype) or if it
is a more widespread phenomenon among other dengue viruses. The 1995 Am-DENV-2 out-
break occurred 5 years after the start of a DENV-1 outbreak, which apparently modulated dis-
ease outcomes [9,18]. No cases of severe disease were observed during the Am-DENV-2
outbreak despite large numbers of secondary infections [18], and DENV-1 antibodies showed
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cross-neutralization against Am-DENV-2 in vitro [9]. These data suggest the possibility that
viral replication during Am-DENV-2 infection was suppressed by DENV-1 antibodies, which
may have modified the immune response to Am-DENV-2 infection. Alternatively, the occur-
rence of DENV-2 re-infection may be a reflection of the overall diversity within the serotype.
Within the E gene coding region, there is approximately 10% nucleotide divergence and 2%
amino acid divergence between Am-DENV-2 and AA-DENV-2. Am-DENV-2 has been
shown to differ from Asian and American/Asian genotypes phenotypically, including replica-
tion in tissue culture and incubation periods in mosquitoes[30,31]. Further, for other arthro-
pod-borne viruses and influenza viruses, a few amino acid changes can have profound
antigenic and epidemiological consequences [32].
There is some support for re-infection with a homologous DENV serotype in animal and in
vitro studies, although most studies do not utilize naturally occurring virus variants and do not
challenge hosts with a different genotype of a homologous serotype. In vaccine studies in non-
human primates, viremia may be attenuated but detectable despite the presence of a robust
immune response [33]. Even when viremia is undetectable, sufficient viral replication occurs to
stimulate homotypic antibody boosting [10]. In one challenge study, four of five monkeys had
detectable viremia upon challenge with an Asian genotype of DENV-2 following primary infec-
tion by different DENV-2 genotypes, indicating a lack of sterile immunity [34]. For virus neu-
tralization studies using sera from vaccinated and naturally infected humans [9,27], monkeys,
and mice, there are often marked genotype-dependent differences in neutralization capacity
[11], some greater than 100-fold. Similarly, monoclonal antibodies vary greatly in their neutral-
izing activity in cell culture and protective efficacy in mice [11]. We found quantitative, but not
qualitative, differences in neutralization of Am-DENV-2 compared with AA-DENV-2
(Table 3). Together with our data, these neutralization results support the need to re-evaluate
underlying assumptions about the epidemiological importance of genotypic differences in neu-
tralization capacity [11].
To our knowledge, this is the first study to present epidemiological data as evidence for
homologous reinfection by DENV. Numerous other studies have noted a poor correlation
between pre-existing virus neutralization antibody titers and clinical protection, both in natural
infection [27,28] and vaccine trials [12,35]. For example, in a Thai cohort [27], pre-existing
DENV-2 antibodies were detected in 60% of DENV-2 infections. Notably, there was one
DENV-2 case with pre-existing monotypic PRNT pattern for DENV-2, suggestive of re-infec-
tion. In an ongoing clinic-based surveillance system in Puerto Rico, one individual had two dis-
tinct DENV-2 episodes, detected by RT-PCR, 16 months apart [36]. It is possible that
homologous reinfection has occurred in other settings and our awareness of this phenomenon
is limited by the large number of subclinical cases, study designs, and diagnostics constrains.
For example, genotype replacement events are not commonly documented in detail [7]. More-
over, unlike our studies in Iquitos, most community-based cohort studies are short term or
monitor only children [7,27], thus it is not possible to carryout long-term follow-up across dif-
ferent age groups. Most available long-term dengue datasets include only severe, hospitalized
cases, which may not be representative of actual virus transmission dynamics. However, an
analysis of 323 virologically confirmed sequential infections in Thailand, based largely on 17
years of hospital-based passive surveillance, did not detect cases of homologous re-infection
[37]. Further, homologous challenge studies in humans conducted in the 1940s by Albert Sabin
did not find evidence for re-infection. The Sabin challenge studies were conducted, however,
over a short time frame (< 18 months) with a small sample of participants and utilized the same
DENV-2 strain for initial infection and challenge [3]. In our study we did not detect any individ-
uals with virologically-confirmed acute DENV-2 infections in both 1995 and 2010–2011, likely
in large part because of limitations of febrile surveillance activities in the mid-1990s and
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challenges in linking participant samples from across studies and years. Subsequent studies
should be designed to track individuals’DENV infections over longer time periods to confirm
our findings and to determine the relevance of re-infection to DENV transmission dynamics.
Conclusions
Consistent with other reports [24,27,28], our data demonstrate that the presence of detectable
neutralizing antibodies does not necessarily correlate with protection from a homologous sero-
type challenge. Although cross-neutralizing antibodies do arise from heterologous serotype
infection [11], our data indicate that the majority of neutralizing antibodies were from prior
infection and thus our results are consistent with widespread homologous re-infection by
DENV-2. Our results have direct implications for current approaches for design and develop-
ment of dengue vaccines. In recent phase 2b and phase 3 trials, a high proportion of vaccinated
individuals developed neutralizing antibodies, with geometric mean titers exceeding 140 for all
serotypes, yet protective efficacy against DENV-2 was far from complete (<50%) [12,24].
Although viral interference has been suggested as one explanation for the vaccine failure, fol-
lowing the Phase 2b results from Thailand, Sabchareon and colleagues speculated that anti-
genic mismatch between the DENV-2 component of the vaccine (Thai strain PUO-218 [38];
Asian 1 genotype) and infecting strains could have led to the limited clinical efficacy [24][39].
Our results indicate that success of a vaccine based on a single strain of each serotype may be
dependent on circulating strains and suggest a potential need to match the vaccine strain with
local circulating variants. There is an urgent need for better in vitromeasures of protection,
because positive PRNT results do not accurately predict protection from symptomatic infec-
tion, particularly at the liberal cutoffs used in vaccine immunogenicity studies (e.g., 50% reduc-
tion with 1:10 dilution of serum).
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